Bithalamical Deep Brain Stimulation in Tourette Syndrome Is Associated with Reduction in Dopaminergic Transmission

Vernaleken, Ingo; Kuhn, Jens; Lenartz, Doris; Raptis, Mardjan; Huff, Wolfgang; Janouschek, Hildegard; Neuner, Irene; Schaefer, Wolfgang M.; Gründer, Gerhard; Sturm, Volker

doi:10.1016/j.biopsych.2009.06.025

Cited by 55 publications

(41 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The subjects in this study included healthy control subjects, patients suffering from schizophrenia, and subjects undergoing deep brain stimulation to treat Tourette's syndrome. After deep brain stimulation and in schizophrenic patients, D 2/3 receptor availability was elevated in various brain regions including the basal ganglia (Laruelle, 1998;Vernaleken et al, 2009). In particular, deep brain stimulation caused BP ND elevations that exceeded previously measured BP ND values (Vernaleken et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

“…After deep brain stimulation and in schizophrenic patients, D 2/3 receptor availability was elevated in various brain regions including the basal ganglia (Laruelle, 1998;Vernaleken et al, 2009). In particular, deep brain stimulation caused BP ND elevations that exceeded previously measured BP ND values (Vernaleken et al, 2009). However, the outliers mentioned above (equilibrium later than 180 minutes) were subjects from the control group.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The applicability of SRTM in [¹⁸F]fallypride PET investigations: Impact of scan durations

Vernaleken

Peters

Raptis

et al. 2011

J Cereb Blood Flow Metab

Self Cite

View full text Add to dashboard Cite

The high-affinity radioligand [18 F]fallypride (FP) is frequently used for quantification of striatal/ extrastriatal D 2/3 receptors and the receptor occupancies of antipsychotics (APs). Its 110 minutes half-life allows long scan durations. However, the optimum scan duration is a matter of debate. This investigation focuses on scan-duration-related effects on simplified reference tissue model (SRTM) results and the time point of transient equilibrium in a large sample of dynamic FP positron emission tomography (PET) scans. Fifty drug-free and 50 AP-treated subjects underwent FP-PET scans (180 minutes scan duration). The binding potential (BP ND ) of the putamen, thalamus, and temporal cortex were calculated using the SRTM and the transient equilibrium model. Furthermore, receptor occupancies were calculated for AP-treated patients. Transient equilibrium in the unblocked putamen occurred after 121 ± 29.6 minutes. The transient equilibrium occurred much earlier in the extrastriatal regions or under AP treatment. Stepwise scan shortening caused BP ND underestimations of 0.58% for the first 10-minute reduction (putamen, SRTM), finally reaching 5.76% after 1 hour scan-time reduction. We observed preferential extrastriatal AP binding irrespective of the analytical method. [18 F]fallypride scan durations of 180 minutes reliably reach equilibrium even in D 2/3 -receptor-rich regions. Moderate reductions in FP scan durations only caused small changes to SRTM results even in receptor-rich regions. Apparently, the D 2/3 receptor occupancy results of APs, especially preferential extrastriatal binding observations, are not relevantly biased by inappropriate scan durations.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The applicability of SRTM in [¹⁸F]fallypride PET investigations: Impact of scan durations

Vernaleken

Peters

Raptis

et al. 2011

J Cereb Blood Flow Metab

Self Cite

View full text Add to dashboard Cite

show abstract

“…The results of DBS from a total of nine different targets have been described. Thalamic targets have included: the thalamus at the crosspoint of CM-Spv-Voi, based on the thalamotomies performed by Hassler (Visser-Vandewalle et al, 2003;Ackermans et al, 2011;Maciunas et al, 2007;Bajwa et al, 2007), a thalamic target that is 2 mm more anterior than the Hassler target (Servello et al, 2008), the center of the cm-pf (Welter et al, 2008;Shields et al, 2008), dorsomedial thalamic nucleus and the ventromedial/ventrolateral region (Vernaleken et al, 2009;Huys et al, 2014). The pallidal targets have included: the GPi at the ventroposterolateral motor portion ( Van der Linden et al, 2002;Diederich et al, 2005;Shahed et al, 2007;Dehning et al, 2008;Dueck et al, 2009), and the anteromedial limbic GPi (Welter et al, 2008).…”

Section: Resultsmentioning

confidence: 99%

“…A further report documents the response to DBS of the dorsomedial nucleus of the thalamus in a single patient with TS (Vernaleken et al, 2009). Following unsuccessful DBS of the globus pallidus internus (GPi) (anteromedial part), the DBS leads were removed and replaced with thalamic leads.…”

Section: Thalamusmentioning

confidence: 99%

Deep Brain Stimulation for Tourette syndrome: The Current State of the Field

Visser‐Vandewalle

Huys

Neuner

et al. 2014

Journal of Obsessive-Compulsive and Related Disorders

Self Cite

View full text Add to dashboard Cite

“…The search yielded a total of 49 articles; 10 articles related to MDD, 22 to OCD, and 17 to TS. Of the articles retrieved, there were a total of 24 included in the analysis, 4 relating to MDD (n = 48) [1,2,3,4], 10 to OCD (n = 64) [5,6,7,8,9,10,11,12,13,14], and 10 to TS (n = 46) [15,16,17,18,19,20,21,22,23,24]. …”

Section: Methodsmentioning

confidence: 99%

Deep Brain Stimulation for Psychiatric Diseases: A Pooled Analysis of Published Studies Employing Disease-Specific Standardized Outcome Scales

Nangunoori¹,

Tomycz²,

Quigley³

et al. 2013

Stereotact Funct Neurosurg

View full text Add to dashboard Cite

Background: Deep brain stimulation (DBS) has emerged in recent years as a novel therapy in the treatment of refractory psychiatric disease, including major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and Tourette's syndrome (TS). Standardized outcome scales were crucial in establishing that DBS was an effective therapy for movement disorders. Objective: In order to better characterize the evidence supporting DBS for various psychiatric diseases, we performed a pooled analysis of those studies which incorporated specific standardized rating scales. Methods: A Medline search was conducted to identify all studies reporting DBS for MDD, OCD, and TS. The search yielded a total of 49 articles, of which 24 were included: 4 related to MDD (n = 48), 10 to OCD (n = 64), and 10 to TS (n = 46). Results: A meta-analysis of DBS for MDD, OCD, and TS in studies employing disease-specific standardized outcome scales showed that the outcome scales all improved in a statistically significant fashion for these psychiatric diseases. Our pooled analysis suggests that DBS for TS has the highest efficacy amongst the psychiatric diseases currently being treated with DBS, followed by OCD and MDD. Conclusion: DBS for psychiatric diseases remains investigational; however, even when studies failing to incorporate standardized outcome scales are excluded, there is statistically significant evidence that DBS can improve symptoms in MDD, OCD, and TS. Standardized disease-specific outcome scales facilitate pooled analysis and should be a required metric in future studies of DBS for psychiatric disease.

show abstract

Bithalamical Deep Brain Stimulation in Tourette Syndrome Is Associated with Reduction in Dopaminergic Transmission

Cited by 55 publications

References 9 publications

The applicability of SRTM in [¹⁸F]fallypride PET investigations: Impact of scan durations

The applicability of SRTM in [¹⁸F]fallypride PET investigations: Impact of scan durations

Deep Brain Stimulation for Tourette syndrome: The Current State of the Field

Deep Brain Stimulation for Psychiatric Diseases: A Pooled Analysis of Published Studies Employing Disease-Specific Standardized Outcome Scales

Contact Info

Product

Resources

About

Bithalamical Deep Brain Stimulation in Tourette Syndrome Is Associated with Reduction in Dopaminergic Transmission

Cited by 55 publications

References 9 publications

The applicability of SRTM in [18F]fallypride PET investigations: Impact of scan durations

The applicability of SRTM in [18F]fallypride PET investigations: Impact of scan durations

Deep Brain Stimulation for Tourette syndrome: The Current State of the Field

Deep Brain Stimulation for Psychiatric Diseases: A Pooled Analysis of Published Studies Employing Disease-Specific Standardized Outcome Scales

Contact Info

Product

Resources

About

The applicability of SRTM in [¹⁸F]fallypride PET investigations: Impact of scan durations

The applicability of SRTM in [¹⁸F]fallypride PET investigations: Impact of scan durations